The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.
 
Yuan Xia
No Relationships to Disclose
 
Wenqian Yang
No Relationships to Disclose
 
Ya-Ping Yang
No Relationships to Disclose
 
Yingying Zhu
No Relationships to Disclose
 
Yinduo Zeng
No Relationships to Disclose
 
Tao Qin
No Relationships to Disclose
 
Shijie Jia
No Relationships to Disclose
 
Jiayi Chen
No Relationships to Disclose
 
Chang Gong
No Relationships to Disclose